Nemolizumab(Nemluvio) Instructions:Uses,Dosage, Side Effects

Nemolizumab(Nemluvio) is a monoclonal antibody designed to block the interleukin-31 receptor, playing a significant role in managing prurigo nodularis in adults. This condition, characterized by severe and persistent itching, can be debilitating for patients. NEMLUVIO® provides a targeted approach to alleviate the symptoms, improving quality of life for those affected by the condition.

NEMLUVIO is administered through subcutaneous injections, typically once every four weeks after an initial dose. The product is reconstituted before use and is delivered via a prefilled dual-chamber pen. Clinical evidence suggests that this treatment can offer significant relief from pruritus and associated skin conditions in individuals with prurigo nodularis.